Monte Rosa Therapeutics, Inc. GLUE Debt Securities, Available-for-Sale, Realized Loss
Debt Securities, Available-for-Sale, Realized Loss at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s debt securities, available-for-sale, realized loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s debt securities, available-for-sale, realized loss?
- Monte Rosa Therapeutics, Inc. (GLUE) reported debt securities, available-for-sale, realized loss of $974K in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s debt securities, available-for-sale, realized loss changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s debt securities, available-for-sale, realized loss increased by 4538.1% year-over-year, from $21K to $974K.
- What does debt securities, available-for-sale, realized loss mean?
- This metric captures the realized losses incurred when the company sells debt securities classified as available-for-sale before their maturity. It reflects the impact of market interest rate fluctuations or credit quality changes on the company's investment portfolio performance. Investors track this to evaluate the effectiveness of the company's treasury management and the volatility of its non-operating investment activities.